Meningioma Prevention
Meningioma Prevention
Meningioma cannot be prevented, and there is no screening test for it. Scanning people without symptoms is not recommended, because the tumour is often slow-growing and harmless, and because an incidental finding brings its own consequences. What does exist is a defined surveillance programme for people with an inherited condition, a clear way of handling a tumour found incidentally, and a structured follow-up after treatment. The useful measures in this disease are about what happens after a finding, not about preventing it.
Why there is no screening programme
The question is asked more often here than in most tumours, because meningiomas are so often found by chance. The answer has three parts:
- Most of these tumours do not harm the person who has them. Many grow very slowly, cause no symptoms and never need treatment, so a screening programme would find a large number of tumours that would have been better left undiscovered.
- An incidental finding has consequences. A tumour found without a reason leads to scans at intervals, sometimes to an operation, and always to a period of uncertainty — and where the tumour would never have caused a problem, none of that brings benefit.
- No benefit from screening has been demonstrated. For a tumour with this behaviour, no study has shown that finding it earlier in people without symptoms changes the outcome.
- Symptoms are the practical route to diagnosis when a tumour is causing something, and the next sections set out what to do with a finding that arrives without symptoms.
The exposure that can be limited
The avoidable share of the risk is small, and it is worth describing accurately rather than offering measures without evidence:
- Therapeutic radiotherapy to the head is the established factor, particularly when given in childhood. It is rarely something a patient controls, since it is given to treat another condition.
- Diagnostic imaging has not been established as a cause. The dose from a CT or MRI is far lower than from therapeutic radiotherapy, and no link to meningioma has been demonstrated.
- The reasonable principle is to avoid unnecessary examinations rather than to avoid necessary ones. Where an investigation will change what is done, it should be done; where it will not, it is reasonable to ask why it is being requested.
- Nothing else has an evidence base. No diet, supplement or protective measure has been shown to reduce the chance of developing this tumour, and products marketed for that purpose should be treated with caution.
Surveillance in the inherited conditions
This is the one situation in which imaging is used to look for meningiomas before they cause symptoms, because the risk is high enough to justify it and a schedule is already defined:
- Neurofibromatosis type 2 — an established programme covering the brain and the spine, which detects meningiomas along with the other tumours the condition causes, often at a stage when treatment is straightforward.
- Other inherited predispositions — where a specific gene change has been identified in a family, surveillance is arranged according to what that change is associated with, under specialist supervision.
- What surveillance is looking for — not only new tumours but growth of those already known, since the decision to treat usually rests on growth rather than on the mere presence of a tumour.
- What to do if you have one of these diagnoses — follow the schedule set out for your condition and tell any new clinician about it, because the schedule is specific rather than general, and a scan planned for one purpose may not cover another.
What to do about a tumour found by chance
A meningioma found on a scan performed for something else is now a common situation, and the way it is handled has become fairly standard:
- Establish what it is and where it sits. Contrast-enhanced MRI, and imaging of the veins if the tumour lies against one, to describe its attachment and its relationship to the structures nearby.
- Decide whether it needs anything now. A small tumour causing no symptoms, not pressing on the nerves of sight or on the flow of fluid, and with no features suggesting a higher grade, is usually observed.
- Set a schedule and put it in writing. Imaging at intervals, more frequent at first and widening if the tumour proves quiet, with the dates recorded and one centre holding the images so that comparisons can be made.
- Ask what would end the observation. Growth between scans, the appearance of symptoms, or a change in position relative to a critical structure should each be stated in advance rather than left to be discovered.
- Do not treat a scan in isolation. A single measurement means little without a comparison; the earlier images are what carry the information, and they should be requested rather than assumed to be unavailable.
Symptoms that should be assessed
Because there is no screening programme, the practical substitute is knowing which symptoms warrant assessment rather than a scheduled scan:
- A first seizure at any adult age always warrants imaging of the brain, whether or not a meningioma is already known.
- Progressive loss of vision, or double vision — treated as urgent, because the optic nerve does not recover from pressure that continues.
- A headache that is new in character — worst on waking, worse on bending or coughing, and building over weeks rather than fluctuating.
- Weakness, numbness or clumsiness affecting one side, or difficulty finding words.
- Hearing loss or ringing in one ear, with unsteadiness, when there is no ear disease to explain it.
- Loss of the sense of smell in one nostril, or a persistent change in smell or taste, which is easily attributed to sinus disease and is worth imaging when it persists.
- Any new symptom in someone under surveillance — reported rather than fitted into the next scheduled scan.
What follow-up looks like
Follow-up after treatment for a meningioma has a defined structure, and knowing it makes the process manageable:
- MRI at defined intervals, more frequent in the first period after treatment and then widening, with the schedule given in writing and each scan compared with the previous one.
- What is being watched for — growth of the tumour, a change at the site where it was removed, and, after radiation, the slow shrinkage that may continue for months or years.
- Seizure control and medication review, aiming to keep seizures controlled while reducing medication where that is safe, and with advice about driving and other activities given explicitly.
- Vision, hearing and hormonal function, where the tumour lay near the structures responsible for them, since a change may develop gradually and be detected by testing before it is noticed.
- Rehabilitation continued after treatment ends, because functional recovery extends well beyond the period of hospital care.
- What to report between scans — a new seizure, a new focal deficit, a change in vision or hearing, headache that is increasing or waking the patient, or increasing drowsiness.